874299-21-5 Usage
Chemical structure
A urea derivative with a phenyl group, a boron-containing dioxaborolane ring, and a trifluoro-ethyl group as substituents.
Functional groups
Phenyl, urea, dioxaborolane, and trifluoro-ethyl.
Boron-containing ring
The compound features a 4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl group, which can interact with enzymes and receptors in biological systems.
Potential applications
Medicinal chemistry, specifically in the development of new drugs with biological activity, and other research and industrial processes.
Biological activity
The compound may have potential applications in medicinal chemistry due to its ability to interact with certain enzymes and receptors.
Industrial processes
The compound may be used in various research and industrial processes, depending on its specific formulation and application.
Chemical stability
The compound's stability and reactivity would depend on the specific conditions and environment it is exposed to.
Solubility
The solubility of the compound in different solvents would depend on its specific formulation and functional groups.
Purity
The purity of the compound would be an important factor in determining its effectiveness and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 874299-21-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,2,9 and 9 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 874299-21:
(8*8)+(7*7)+(6*4)+(5*2)+(4*9)+(3*9)+(2*2)+(1*1)=215
215 % 10 = 5
So 874299-21-5 is a valid CAS Registry Number.
874299-21-5Relevant academic research and scientific papers
SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION
-
, (2013/05/22)
The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2
BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE
-
, (2012/02/15)
The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
-
, (2010/01/07)
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
